262 related articles for article (PubMed ID: 16605112)
1. Clinical significance of aflatoxin, mutant P53 gene and sIL-2 receptor in liver cirrhosis and hepatocellular carcinoma.
El-Shanawani FM; Abdel-Hadi AA; Abu Zikri NB; Ismail A; El-Ansary M; El-Raai A
J Egypt Soc Parasitol; 2006 Apr; 36(1):221-39. PubMed ID: 16605112
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies.
Stern MC; Umbach DM; Yu MC; London SJ; Zhang ZQ; Taylor JA
Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):617-25. PubMed ID: 11401911
[TBL] [Abstract][Full Text] [Related]
3. Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan.
Shirabe K; Toshima T; Taketomi A; Taguchi K; Yoshizumi T; Uchiyama H; Harimoto N; Kajiyama K; Egashira A; Maehara Y
Liver Int; 2011 Oct; 31(9):1366-72. PubMed ID: 21745313
[TBL] [Abstract][Full Text] [Related]
4. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
5. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure.
Qi LN; Bai T; Chen ZS; Wu FX; Chen YY; De Xiang B; Peng T; Han ZG; Li LQ
Liver Int; 2015 Mar; 35(3):999-1009. PubMed ID: 24461059
[TBL] [Abstract][Full Text] [Related]
6. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China.
Ming L; Thorgeirsson SS; Gail MH; Lu P; Harris CC; Wang N; Shao Y; Wu Z; Liu G; Wang X; Sun Z
Hepatology; 2002 Nov; 36(5):1214-20. PubMed ID: 12395332
[TBL] [Abstract][Full Text] [Related]
7. 249(ser) TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.
Kirk GD; Lesi OA; Mendy M; Szymañska K; Whittle H; Goedert JJ; Hainaut P; Montesano R
Oncogene; 2005 Sep; 24(38):5858-67. PubMed ID: 16007211
[TBL] [Abstract][Full Text] [Related]
8. Does aflatoxin B1 play a role in the etiology of hepatocellular carcinoma in the United States?
Hoque A; Patt YZ; Yoffe B; Groopman JD; Greenblatt MS; Zhang YJ; Santella RM
Nutr Cancer; 1999; 35(1):27-33. PubMed ID: 10624703
[TBL] [Abstract][Full Text] [Related]
9. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan.
Lunn RM; Zhang YJ; Wang LY; Chen CJ; Lee PH; Lee CS; Tsai WY; Santella RM
Cancer Res; 1997 Aug; 57(16):3471-7. PubMed ID: 9270015
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
Kitaoka S; Shiota G; Kawasaki H
Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
[TBL] [Abstract][Full Text] [Related]
11. Plasma 249Ser p53 mutation in patients with hepatocellular carcinoma residing in a high risk area.
Dong-Dong L; Xi-Ran Z
J Cell Mol Med; 2003; 7(1):89-92. PubMed ID: 12767266
[TBL] [Abstract][Full Text] [Related]
12. [p53 gene mutation in hepatocellular carcinoma].
Jiang W; Lu Q; Pan G
Zhonghua Wai Ke Za Zhi; 1998 Sep; 36(9):531-2. PubMed ID: 11825456
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of plasma TP53 249Ser-mutated DNA by electrospray ionization mass spectrometry.
Lleonart ME; Kirk GD; Villar S; Lesi OA; Dasgupta A; Goedert JJ; Mendy M; Hollstein MC; Montesano R; Groopman JD; Hainaut P; Friesen MD
Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2956-62. PubMed ID: 16365016
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
[TBL] [Abstract][Full Text] [Related]
15. [Universal presence of HBVx gene and its close association with hotspot mutation of p53 gene in hepatocellular carcinoma of prevalent area in China].
Zhang F; Zhu Y; Sun Z
Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):18-21. PubMed ID: 10921048
[TBL] [Abstract][Full Text] [Related]
16. Geographic characterization of hepatitis virus infections, genotyping of hepatitis B virus, and p53 mutation in hepatocellular carcinoma analyzed by in situ detection of viral genomes from carcinoma tissues: comparison among six different countries.
Ding X; Park YN; Taltavull TC; Thung SN; Jin X; Jin Y; Trung NS; Edamoto Y; Sata T; Abe K
Jpn J Infect Dis; 2003 Feb; 56(1):12-8. PubMed ID: 12711820
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53 protein in liver and sera of patients with liver fibrosis, liver cirrhosis or hepatocellular carcinoma associated with chronic HCV infection.
Attallah AM; Shiha GE; Ismail H; Mansy SE; El-Sherbiny R; El-Dosoky I
Clin Biochem; 2009 Apr; 42(6):455-61. PubMed ID: 19063876
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B 1762T/1764A mutations, hepatitis C infection, and codon 249 p53 mutations in hepatocellular carcinomas from Thailand.
Kuang SY; Lekawanvijit S; Maneekarn N; Thongsawat S; Brodovicz K; Nelson K; Groopman JD
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):380-4. PubMed ID: 15734961
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis.
Wang Y; Liu YH; Mai SJ; He LJ; Liao YJ; Deng HX; Guan XY; Zeng YX; Kung HF; Xie D
J Gastroenterol Hepatol; 2010 Jun; 25(6):1123-8. PubMed ID: 20594228
[TBL] [Abstract][Full Text] [Related]
20. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.
Hosny G; Farahat N; Tayel H; Hainaut P
Cancer Lett; 2008 Jun; 264(2):201-8. PubMed ID: 18313840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
